Rock Creek Pharmaceuticals Inc. (fka RCPIQ)

[Buddhahead]

NF-kB as target for Parkinson's Disease Therapy at Michael J. Fox Foundation For Parkinson's Research, Therapeutics Development Initiative, 2007

Objective/Rationale:
"Chronic inflammation mediated by microglial cells is the fundamental process contributing to the death of dopamine producing neurons in the brain. Production of inflammatory products by these microglial cells characterizes the slow destructive process in Parkinson’s disease. NF-?B is a protein which controls the expression of over 200 genes critical in inflammation and the immune response within the microglial cell, and we believe that therapies aimed at inhibiting the expression of NF-kB will be successful in reversing or slowing the progression of Parkinson’s disease. "

Webpage at:
https://www.michaeljfox.org/foundation/grant-detail.php?grant_id=394